Clinical Research Directory
Browse clinical research sites, groups, and studies.
The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
Sponsor: University of Calgary
Summary
The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE: blood clots in the legs or lungs) for postpartum individuals with VTE risk factors.
Official title: The PARTUM (Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity) Trial
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
8805
Start Date
2025-04
Completion Date
2030-12
Last Updated
2025-03-03
Healthy Volunteers
No
Interventions
Aspirin
75-100 mg taken once daily by mouth.
Low-molecular-weight heparin
Low-molecular-weight heparin injections daily as prescribed by the treating physician.
Locations (3)
Foothills Medical Centre
Calgary, Alberta, Canada
The Ottawa Hospital - General Campus
Ottawa, Ontario, Canada
Mount Sinai Hospital
Toronto, Ontario, Canada